The white, round tablet imprinted with “AN 627” is an immediate-release prescription drug containing Tramadol Hydrochloride 50 mg. Manufactured primarily by Amneal Pharmaceuticals, it is a centrally acting synthetic opioid analgesic indicated for managing pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Pill Identification
Physical Property – Specification
- Active Ingredient – Tramadol Hydrochloride (50 mg)
- Imprint Code –
AN 627 - Color – White
- Shape – Round
- Manufacturer – Amneal Pharmaceuticals
- Drug Class – Centrally Acting Synthetic Opioid Analgesic
- Controlled Status – DEA Schedule IV Controlled Substance
Mechanism of Action
Tramadol features a dual mechanism of action that differentiates it from traditional pure opioid agonists:
- Opioid Receptor Agonism: Tramadol and its primary active metabolite, desmethyltramadol (M1), bind weak-to-moderately to opioid receptors on neuronal membranes. This suppresses presynaptic neurotransmitter release, inhibiting nociceptive pain signal transmission in the central nervous system (CNS).
- Monoamine Reuptake Inhibition: Tramadol simultaneously inhibits the neuronal reuptake of two key neurotransmitters involved in descending pain pathways:
- Serotonin (5-HT): Enhances serotonergic pathways that modulate central pain transmission.
- Norepinephrine (NE): Increases synaptic norepinephrine levels, activating adrenergic receptors in the spinal cord to inhibit pain propagation.
Indications & Dosage
Primary Indications
Tramadol 50 mg is indicated for managing acute and chronic moderate-to-severe pain in adults when non-opioid options (such as NSAIDs or acetaminophen) are insufficient or contraindicated.
Dosage Guidelines
- Standard Adult Dosing (Immediate-Release): Typically 50 mg to 100 mg orally every 4 to 6 hours as needed for pain relief.
- Maximum Daily Limit: 400 mg per day (equivalent to 8 of the AN 627 tablets) in patients with normal renal and hepatic function.
- Elderly Patients (>75 years): Total daily dose should not exceed 300 mg per day due to decreased systemic drug clearance.
- Renal/Hepatic Impairment: Dosing intervals must be extended (e.g., 50 mg every 12 hours) in patients with severe renal or hepatic insufficiency.
Side Effects
Common Side Effects
- Gastrointestinal: Nausea, vomiting, constipation, dry mouth, indigestion (dyspepsia).
- Central Nervous System: Dizziness, somnolence (drowsiness), headache, agitation, anxiety, sweating, or mild tremors.
Serious Adverse Reactions
- Seizures: Tramadol can lower the seizure threshold, causing convulsions even at recommended doses.
- Serotonin Syndrome: A severe, potentially life-threatening reaction marked by mental status changes, hyperreflexia, fever, rapid heart rate, and neuromuscular instability when combined with serotonergic drugs.
- Severe Respiratory Depression: Slow, shallow, or difficult breathing, particularly when starting therapy or escalating doses.
- Adrenal Insufficiency: Prolonged use can impair adrenal hormone production, leading to fatigue, anorexia, dizziness, and low blood pressure.
Boxed Warnings & Key Safety Precautions
FDA Black Box Warnings
- Addiction, Abuse, and Misuse: Tramadol carries a risk of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess risk prior to prescribing.
- Life-Threatening Respiratory Depression: Serious or fatal respiratory depression can occur, especially in elderly, debilitated, or opioid-naïve patients.
- Accidental Ingestion: Ingestion of even one dose by children or non-prescribed individuals can cause a fatal overdose.
- Ultra-Rapid Metabolism (CYP2D6): Ultra-rapid metabolizers convert tramadol into its active metabolite M1 far more quickly, causing unexpectedly high opioid levels and life-threatening respiratory depression. Contraindicated in pediatric patients under 12 years old and post-tonsillectomy/adenoidectomy in patients under 18.
- Concomitant Use with CNS Depressants: Co-administration with benzodiazepines, alcohol, or other sedatives increases the risk of profound sedation, respiratory depression, coma, and death. >
Drug Interactions & Overdose Management
Critical Drug Interactions
- Serotonergic Drugs (SSRIs, SNRIs, Triptans, MAOIs): Combined use drastically increases the risk of Serotonin Syndrome and seizures. MAOIs must be discontinued at least 14 days prior to starting tramadol.
- CYP2D6 & CYP3A4 Inhibitors/Inducers: Drugs like fluoxetine or paroxetine inhibit CYP2D6, altering active metabolite levels. CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) raise tramadol concentrations, escalating seizure and toxicity risks.
- Sedatives & CNS Depressants: Amplifies respiratory suppression and profound sedation.
Overdose Signs & Immediate Action
- Overdose Symptoms: Respiratory depression (slow or stopped breathing), extreme drowsiness, limp muscles, cold/clammy skin, pinpoint pupils, bradycardia, or seizures.
- Emergency Response: Call 911 immediately. Administer Naloxone (Narcan) to reverse opioid-mediated effects. Note that while naloxone reverses respiratory depression, it may increase the risk of seizures in tramadol toxicity; continuous emergency medical supervision is required.